SunTrust Banks, Inc. set a $101.00 price target on Spark Therapeutics, Inc. (NASDAQ:ONCE) in a research note released on Monday. The firm currently has a buy rating on the biotechnology company’s stock.
Several other brokerages have also commented on ONCE. ValuEngine raised Spark Therapeutics from a sell rating to a hold rating in a research note on Tuesday, June 20th. BidaskClub raised Spark Therapeutics from a sell rating to a hold rating in a research note on Thursday, June 22nd. William Blair began coverage on Spark Therapeutics in a research note on Wednesday, June 28th. They issued an outperform rating on the stock. Jefferies Group LLC began coverage on Spark Therapeutics in a research note on Monday, July 10th. They issued a buy rating and a $85.00 price target on the stock. Finally, Zacks Investment Research lowered Spark Therapeutics from a hold rating to a sell rating in a research note on Wednesday, July 12th. Two analysts have rated the stock with a sell rating, two have given a hold rating and eighteen have given a buy rating to the company. The stock currently has an average rating of Buy and a consensus target price of $90.47.
Shares of Spark Therapeutics (ONCE) opened at 80.79 on Monday. The stock’s market cap is $2.52 billion. Spark Therapeutics has a 12-month low of $35.07 and a 12-month high of $91.75. The company’s 50-day moving average price is $85.44 and its 200 day moving average price is $85.44.
Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.75) by ($0.14). The company had revenue of $1.48 million for the quarter, compared to analyst estimates of $1.33 million. Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. The business’s quarterly revenue was up 14.7% on a year-over-year basis. During the same period last year, the firm posted ($1.04) EPS. On average, equities analysts predict that Spark Therapeutics will post ($7.59) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “SunTrust Banks, Inc. Reiterates “$101.00” Price Target for Spark Therapeutics, Inc. (ONCE)” was published by BBNS and is the sole property of of BBNS. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://baseballnewssource.com/markets/suntrust-banks-inc-reiterates-101-00-price-target-for-spark-therapeutics-inc-once/1719687.html.
In other Spark Therapeutics news, Director Hospital Of Philade Children’s sold 1,000,000 shares of the company’s stock in a transaction dated Thursday, September 21st. The stock was sold at an average price of $84.63, for a total transaction of $84,630,000.00. Following the sale, the director now owns 3,928,707 shares in the company, valued at approximately $332,486,473.41. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Anand Mehra sold 211,858 shares of the company’s stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $70.15, for a total value of $14,861,838.70. The disclosure for this sale can be found here. Insiders sold a total of 1,333,195 shares of company stock worth $109,070,506 in the last quarter. Company insiders own 7.30% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. increased its holdings in Spark Therapeutics by 11.6% during the 2nd quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock worth $122,689,000 after purchasing an additional 213,520 shares during the period. Vanguard Group Inc. increased its holdings in Spark Therapeutics by 5.3% during the 2nd quarter. Vanguard Group Inc. now owns 1,924,463 shares of the biotechnology company’s stock worth $114,968,000 after purchasing an additional 96,803 shares during the period. JPMorgan Chase & Co. increased its holdings in Spark Therapeutics by 3.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,607,972 shares of the biotechnology company’s stock worth $96,060,000 after purchasing an additional 58,879 shares during the period. Wellington Management Group LLP increased its holdings in Spark Therapeutics by 119.5% during the 1st quarter. Wellington Management Group LLP now owns 808,782 shares of the biotechnology company’s stock worth $43,140,000 after purchasing an additional 440,287 shares during the period. Finally, Janus Henderson Group PLC purchased a new stake in Spark Therapeutics during the 2nd quarter worth about $30,848,000. Institutional investors own 77.84% of the company’s stock.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with our FREE daily email newsletter.